MONOPAR THERAPEUTICS INC (MNPR)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Clinical-stage biopharmaceutical company developing copper-chelating therapies and radiopharmaceutical cancer imaging and treatment agents.
What MONOPAR THERAPEUTICS INC does
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic and imaging agents, with primary emphasis on copper-chelating therapies and radiopharmaceutical technologies. The company's lead program is ALXN1840, a copper chelator for Wilson disease, which completed a pivotal Phase 3 trial meeting its primary endpoint, though the original developer (Alexion/AstraZeneca) terminated the program and Monopar is now assembling a regulatory package for NDA submission. The company is also advancing radiopharmaceutical programs for cancer imaging and treatment, though these face technical challenges including radioisotope supply constraints and novelty-related adoption risks.
Themes: ["Copper-chelating therapies / Wilson disease"]
Fundamentals
- Price$104.50 as of 2026-07-09 close
- Market cap$717M as of 2026-07-10
- 1-year return+158.4% as of 2026-07-09 close
- ROE-12.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.47 as of 2026-07-10
Key risks (from latest filing)
["History of financial losses with no approved products; company is highly dependent on raising additional capital to fund clinical development, regulatory submissions, and commercialization efforts, with uncertain outcomes."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.